Physicians’ actions to help end the nation’s drug-related overdose and death epidemic — and what still needs to be done.
The American Medical Association convened two task forces between 2014–2019 that have provided actionable and measurable recommendations and principles for physicians, state and federal policymakers, and other stakeholders to combat the nation’s drug overdose and death epidemic.

In response, there has been measurable progress by physicians and others across multiple areas and policy changes led by medical society advocacy. Yet, the nation’s drug-related overdose and death epidemic has changed and worsened. As a result, the AMA has united the two task forces to launch a new, collective effort to directly address this changing epidemic: AMA Substance Use and Pain Care Task Force.
Physicians and other health care professionals have reduced opioid prescribing in every state for 10 consecutive years. They have increased the use of state prescription drug monitoring programs (PDMPs) in every state for the past five years. Despite these efforts, drug-related mortality continues to rise.

44.4% decrease in opioid prescriptions from 257.9M in 2011 to 143.4M in 2020

910.6M Increase in PDMP use and 2.7B queries since 2014

106,000+ physicians and health care professionals certified to prescribe buprenorphine in-office—a nearly 70,000 increase since 2017.

Yet, millions with a substance use disorder (SUD) remain without access to evidence-based care.

Prescriptions for buprenorphine and naloxone have increased only marginally in the past three years despite rising mortality. The AMA encourages physicians to prescribe naloxone to patients at risk of overdose.

Harm reduction and other community-based organizations distributed more than 3.7 million doses of naloxone between 2017–2020.

During the COVID-19 pandemic, the number of individuals filling a naloxone prescription from retail pharmacies decreased more than 26%.


The COVID-19 pandemic has exacerbated the nation’s drug overdose and death epidemic.

Every state has reported increases in overdoses during the COVID-19 pandemic. It has affected patients with pain and an SUD, as well as patients who use harm reduction services. Structural racism and health inequities have made the pandemic even worse for marginalized and minoritized individuals.

Drug overdose deaths in 2020 hit highest number ever recorded, CDC data shows
—CNN

Sharp Rise In Drug Overdose Deaths Seen During 1st Few Months Of Pandemic
—NPR

AMA Urges Changes After Dramatic Increase in Illicit Opioid Fatalities
—Medscape

In pandemic, drug overdose deaths soar among Black Americans
—Associated Press News

Chronic pain can be burdensome. Isolation during the pandemic can make it worse.
—Washington Post

Overdose Deaths Surged In Pandemic, As More Drugs Were Laced With Fentanyl
—NBC News

Latinos grapple with opioid overdose rise as pandemic triggers surge in U.S. use
—NBC News

"American Indian and Alaska Native (AI/AN) populations had the second highest overdose rates from all opioids in 2017 (15.7 deaths/100,000 population) among racial/ethnic groups in the US. AI/AN populations also had the second highest overdose death rates from heroin (5.2) and third highest from synthetic opioids (6.5).”

"From 1999 to 2018…[t]he greatest increases were among non-Hispanic Black men for heroin overdose (3.3 in 1999 to 17.7 in 2018) and synthetic opioid overdose (0.1 in 1999 to 36.0 in 2018).”

"From 2014-2017, among the Hispanic population drug overdose death rates involving all types of opioids increased, with the sharpest rise from synthetic opioids. Death rates involving synthetic opioids increased by 617 percent, and was the second highest for Hispanics compared to all other race/ethnicities.”

"The stakes are life and death”: Addiction treatment’s Covid-19 challenge
—Vox

Read about reports in all 50 states: AMA issue brief:
Nation’s drug-related overdose and death epidemic continues to worsen
Stakeholders need to work together to develop comprehensive, state- and community-based solutions and action-oriented efforts to improve outcomes and save lives.

The AMA strongly believes that ending the nation’s drug-related overdose and death epidemic—as well as improving care for patients with pain, mental illness or SUD—requires partnership, collaboration and commitment to individualized patient care decision-making to implement impactful changes, including:

- Urging states to adopt federal telehealth flexibilities to allow for the induction of buprenorphine at home
- Decriminalizing drug checking supplies
- Ensuring opioid litigation funds are used only for public health purposes
- Urging the Centers for Disease Control and Prevention to rescind the arbitrary thresholds in its 2016 opioid prescribing guideline and to restore compassionate care for patients with pain
- Removing structural inequities in care provided to historically marginalized and minoritized communities

Key collaborative AMA efforts in 2020–2021

- Collaboration with the Johns Hopkins School of Public Health and more than 50 national stakeholders has led to over a dozen states enacting laws directing opioid-litigation funds to be used mainly for public health uses.
- Published a national roadmap with Manatt Health to provide tangible actions for policymakers and public health officials to increase access to evidence-based care.
- Worked with the Milken Institute and the Drug Enforcement Administration to promote evidence-based recommendations to help employers increase access to care for pain, SUDs and harm reduction services.
- Partnered with state and specialty societies to help enact several dozen laws and regulations to increase access to medications to treat opioid use disorder, meaningfully enforce mental health and SUD parity laws, decriminalize drug checking supplies and remove barriers to evidence-based care for patients with pain, as well as supported the Rhode Island Medical Society in its campaign to enact the nation’s first harm reduction center pilot program.
- Supported efforts with the American Society of Addiction Medicine, the American Association for the Treatment of Opioid Dependence and other key stakeholders to increase access to care for patients with an opioid use disorder.
- Conducted analysis with the nonpartisan and objective research organization NORC at the University of Chicago to identify the gaps in states’ overdose reporting systems.
- Advocated and provided support for the National Association of Insurance Commissioners to meaningfully address health inequities in its work to advance mental health and SUD parity.
- Joined with medical societies and patient advocates in Oklahoma and Colorado to enact legislation to support individualized patient care decisions for patients with pain, including opioid therapy and non-opioid pain care.
Physicians are ready to work with all stakeholders to develop and implement collaborative, evidence-based solutions to reduce mortality and improve outcomes.

- Public health officials can help control infectious disease spread through supporting comprehensive needle and syringe exchange services.

- Medical and other health care professional licensing boards can help patients with pain by reviewing and rescinding arbitrary restrictions on opioid therapy.

- Policymakers can help increase access to evidence-based SUD care by removing administrative barriers—such as prior authorization—for medications to treat opioid use disorder.

- State officials can demonstrate leadership and support families by removing punitive policies against pregnant, peripartum and parenting individuals who have an SUD.

- Faith leaders can help destigmatize SUDs and harm reduction by educating parishioners and holding overdose awareness events.

To make meaningful progress towards ending this epidemic, a broad-based public health approach is required. This approach must balance patients’ needs for comprehensive pain management services, including access to non-opioid pain care as well as opioid analgesics when clinically appropriate, with efforts to promote appropriate prescribing, reduce diversion and misuse, promote an understanding that substance use disorders are chronic conditions that respond well to evidence-based treatment, and expand access to treatment for individuals with substance use disorders.

—Gerald E. Harmon, MD
President, AMA
Treating the nation’s drug overdose and death epidemic demands a far more proactive and coordinated approach focused on evidence-based, public health solutions.

Evidence and data are essential to helping patients with pain, increasing treatment for SUDs, reducing stigma, and preventing overdose and death.

What we do today:
“Crisis framework”

What we must do tomorrow:
Integrated, sustainable, predictable and resilient public health system

While data is critical to improving outcomes, current data is:
…incomplete
…not standardized for comparison
…not timely
…widely variable from location to location

Difficulties remain in accessing high quality, timely, comprehensive and standardized data. While metrics are generally available for drug-related overdoses, data for non-fatal overdoses and other key indicators are not widely collected or standardized across states and communities. These data gaps greatly hinder understanding of local situations and advancing prevention, treatment and harm reduction efforts.

Inadequate data collection prevents effective public health interventions to reduce overdose and death.

Data categories
- Prescriptions
- PDMP
- Fatal overdoses
- Non-fatal overdoses
- No data
The AMA urges policymakers and other stakeholders to take meaningful action to remove barriers and increase patients’ access to evidence-based care to save lives and help end the epidemic.

1. Remove barriers to evidence-based care for patients with an SUD. This includes removing prior authorization and step therapy for medications to treat opioid use disorder (MOUD), continuing federal flexibilities for take-home medication for opioid treatment programs and continuing telehealth options for patients to begin MOUD.

2. Remove barriers to MOUD and treatment for SUDs and co-occurring mental illness in the nation’s jails and prisons. There is no legal, medical, or policy reason to deny access to MOUD or mental health care for justice involved persons.

3. Take immediate steps to protect families by focusing on increasing access to evidence-based care rather than using punishment and the threat of family separation for persons who are pregnant, peripartum, postpartum and parenting.

4. Support patients with pain by rescinding arbitrary laws and policies focused on restricting access to multidisciplinary, multimodal pain care; require health insurance companies and other payers to make non-opioid pain care alternatives more accessible and affordable, emphasizing social determinants of health.

5. State insurance commissioners, attorneys general and the U.S. Department of Labor must increase efforts to review health insurers’ policies on a regular basis to ensure they comply with the Mental Health Parity and Addiction Equity Act—and hold them accountable if not.

6. Support increased efforts to expand sterile needle and syringe exchange services programs, decriminalize drug checking supplies (e.g., fentanyl test strips) and urge manufacturers to make naloxone available over the counter.

7. Develop and implement systems to collect timely, adequate and standardized data to identify at-risk populations, fully understand polysubstance drug use, and implement public health interventions that directly address removing structural and racial inequities.

Policymakers and other stakeholders have a choice of whether to pursue evidence-based strategies to support patients’ access to lifesaving and life-affirming care. Every effort must be made to remove health inequities and other barriers for patients with substance use disorders, mental illness and patients with pain. More of our loved ones will suffer and die if these barriers remain.

—Bobby Mukkamala, MD
Chair, AMA Substance Use and Pain Care Task Force
These materials include information derived from market research information provided by IQVIA, Inc. ("IQVIA"). IQVIA market research information is proprietary to IQVIA and available by subscription from IQVIA. The IQVIA Xponent® market research data includes estimates of dispensed drug prescription information from retail pharmacies (chain, mass merchandisers, independent and food stores) in the United States. IQVIA sources transaction information for +90% of the retail channel and uses a customized and patented estimation methodology to generate accurate market estimates. IQVIA employs various proprietary methodologies in data sourcing, data receipt, data editing and cleansing, creation and maintenance of reference files, data quality assurance processes, reference data bridging, database management and report creation to produce these estimates. More information about IQVIA can be found at www.IQVIA.com.